SNTA: Synta Pharmaceuticals Soars on Breast Cancer Treatment News

The results were unveiled at a medical conference in Europe

   

SNTA: Synta Pharmaceuticals Soars on Breast Cancer Treatment News

hospital beds SNTA: Synta Pharmaceuticals Soars on Breast Cancer Treatment NewsOn Thursday, Synta Pharmaceuticals (SNTA) said that its breast cancer treatment had shown promising interim results in a trial. The news sent SNTA stock up more than 8% in mid-day trading.

SNTA stock gained after the company said that ganetespib, administered as monotherapy to combat metastatic breast cancer, had demonstrated “highly encouraging single-agent activity in both HER2+ and triple-negative disease” in the ENCHANT-1 trial. The study is a single-arm multi-center Phase 2 proof-of-concept study that aims to assess the drug’s performance. The interim results were presented at the 9th European Breast Cancer Conference (EBCC) in Glasgow, Scotland.

prescription drugs 200x200 SNTA: Synta Pharmaceuticals Soars on Breast Cancer Treatment News
Actavis Prescribes Profits via M&A and Generic Drugs

In a statement, SNTA noted that the early results “warrant expanded study of ganetespib in this metastatic disease setting.”

On Wednesday, SNTA stock closed at $4.75 a share. SNTA stock has declined more than 30% over the past year.

More Drug Stock News:


Article printed from InvestorPlace Media, http://investorplace.com/2014/03/snta-synta-pharmaceuticals-soars-breast-cancer-treatment-news/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.